Page 5 - Borja Ib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive anthracyclines alone or in combination with other anticancer agents. Anthracyclines are a frequently prescribed anticancer agent that can induce an irreversible toxic effect on the heart may lead to chronic heart failure in  ≈5% of the cases. It is estimated that in Europe the prevalence of chronic heart failure secondary to cancer therapy-related cardiotoxicity is ≈1 million people. The trade-off between cancer and chronic heart failure is a massive psychological burden. For healthcare systems, the growing incidence of chronic heart failure has devastating consequences.

Borja ibSophia antipolisEmily hendersonLymphoma coalition europeCouncil of cardioEuropean society of cardiologySpanish national centre for cardiovascular researchEuropean commissionDemographic changeSpanish national centreCardiovascular researchNon hodgkin lymphomaPrincipal investigator coordinatorMobile appEuropean societyEuropean manager